Biologics Contract Development Global Market Report 2024 - By Share, Growth, Demand, Report, Forecast To 2033

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2144

The Business Research Company offers in-depth market insights through Biologics Contract Development Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The biologics contract development market size has grown rapidly in recent years. It will grow from $6.94 billion in 2023 to $7.7 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to biologics market growth, rise in biopharmaceuticals, complexity of biologics, patent expirations, cost efficiency..

The biologics contract development market size is expected to see rapid growth in the next few years. It will grow to $11.68 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to digitalization and data analytics, risk management, flexibility and scalability, burgeoning investment in r&d, precision medicine and personalized therapies.. Major trends in the forecast period include regenerative medicine, risk mitigation strategies, global collaborations, advanced technologies, technological integration..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=8219&type=smp

Market Segmentation:
The biologics contract development market covered in this report is segmented -
1) By Source: Microbial, Mammalian, Others Soruces
2) By Indication: Oncology, Immunological disorders, Cardiovascular disorders, Hematological disorders, Others Indications
3) By Product Service: Cell Line Development, Process Development, Others Product Services

Major Driver - Surge In Chronic Diseases Drives Demand, Fueling Growth In The Biologics Contract Development Market
The rising prevalence of chronic diseases is expected to propel the biologics contract development market going forward. Chronic diseases refer to an illness that lasts for a year or longer that requires ongoing medical attention. The rise in chronic disease cases is increasing the demand for developing novel drugs, including biologics, thereby promoting the biologics contract development market. For instance, according to data published in April 2021 by the World Health Organization, a Switzerland-based health organization for international public health, 41 million people die every year due to chronic diseases globally, close to 71% of all deaths. Therefore, the rising prevalence of chronic diseases will drive the growth of the biologics contract development market.

Competitive Landscape:
Major companies operating in the biologics contract development market report are WuXi Biologics, Abzena Ltd., Fujifilm Diosynth Biotechnologies, KBI Biopharma, AGC Biologics, Thermo Fisher Scientific Inc, LakePharma Inc., GenScript Biotech Corporation, Bionova Scientific Inc., Boehringer Ingelheim GmbH, STC Biologics, Siegfried Evionnaz SA, BioAgilytix Labs Inc., Samsung BioLogics, Forge Biologics, Lonza Group, Catalent Inc., AbbVie Inc., Cytovance Biologics, Emergent BioSolutions, Eurofins CDMO, Meridian Life Science Inc., Merck Group, Patheon N.V., ProBioGen AG, Rentschler Biopharma SE, Sartorius AG, Syngene International Limited, Vibalogics GmbH, Yposkesi, ZymoGenetics Inc.

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Top Trend - Innovative Technological Integration Elevates Biologics Contract Development Market Dynamics Lonza's Bylok Platform Sets A New Standard
Technological advancements are gaining popularity in the biologics contract development market. Major companies in the biologics contract development market are integrating advanced technologies to sustain their position in the market. For instance, in January 2022, Lonza, a Switzerland-based contract manufacturing and development solutions company, launched bYlok technology platform to design and manufacture bispecific antibodies. It helps to solve the light-heavy chain mispairing issue with high yields, >95% accuracy, and the ability to maintain a mAb-like format. It can be accessed by pharma and biotech companies through a simple research license.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Biologics Contract Development Market Characteristics
3. Biologics Contract Development Market Trends And Strategies
4. Biologics Contract Development Market - Macro Economic Scenario
5. Biologics Contract Development Market Size And Growth
…..
27. Biologics Contract Development Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model"

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.